Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: Comparisons over 5 years

Journal of Psychopharmacology

Volumn 24, Issue 10, 2010, Pages 1473-1482

  Patel, M X ^a   Haddad, P M ^b   Chaudhry, I B ^b   McLoughlin, S ^b   David, A S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

adherence; antipsychotics; attitudes; delayed action preparations; injections; schizophrenia

Indexed keywords

FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PIPOTIAZINE PALMITATE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG PREFERENCE; HUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHIATRIST; QUESTIONNAIRE; SCHIZOPHRENIA; STIGMA; TABLET FORMULATION; TREND STUDY; UNITED KINGDOM;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; ENGLAND; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INDIVIDUALIZED MEDICINE; INJECTIONS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT PREFERENCE; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY; QUESTIONNAIRES; SCHIZOPHRENIA;

EID: 77958002310     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109104882     Document Type: Article

References (35)

1. Byerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F., Carmody, T., et al. (2005) A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 133: 129-133.
2. Deslandes, PN, Thomas, A., Faulconbridge, GM, Davies, WC (2007) Experience with risperidone long-acting injection: results of a naturalistic observation study. Int J Psychiatry Clin Pract 11: 207-211.
3. Dunn, G. (1989) Design and Analysis of Reliability Studies: The Statistical Evaluation of Measurement Errors. London: Edward Arnold, pp. 37.
4. Emsley, R., Medori, R., Koen, L., Oosthuizen, PP, Niehaus, DJ, Rabinowitz, J. (2008) Long-acting injectable risperidone in the treatment of subjects with recent onset psychosis: a preliminary study. J Clin Psychopharmacol 28: 210-213.
5. Gilmer, TP, Dolder, CR, Lacro, JP, Folsom, DP, Lindamer, L., Garcia, P., et al. (2004) Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 161: 692-699.
6. Glazer, WM (2007) The depot paradox. Behav Healthc 27: 44-46.
7. Haddad, P., Dursun, SM (2006) Selecting antipsychotics in schizophrenia: lessons from CATIE. J Psychopharmacol 20: 332-334.
8. Haddad, PM, Sharma, SG (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911-936.
9. Heres, S., Hamann, J., Kissling, W., Leucht, S. (2006) Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 67: 1948-1953.
10. Heres, S., Schmitz, FS, Leucht, S., Pajonk, FG (2007) The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 22: 275-282.
11. Kane, JM, Aguglia, E., Altamura, AC, Ayuso Gutierrez, JL, Brunello, N., Fleischhacker, WW, et al. (1998) Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8: 55-66.
12. Kane, JM, Eerdekens, M., Lindenmayer, J-P., Keith, SJ, Lesem, M., Karcher, K. (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125-1132.
13. Kreyenbuhl, JA, Valenstein, M., McCarthy, JF, Ganoczy, D., Blow, FC (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 58: 489-495.
14. Lambert, T., Brennan, A., Castle, D., Kelly, DL, Conley, RR (2003) Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract 9: 252-260.
15. Mark, TL (2004) Preferences among antipsychotic medications given particular clinical scenarios. Schizophr Res 66: 71-73.
16. Moore, TA, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML, et al. (2007) The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68: 1751-1762.
17. Nasrallah, HA (2007) The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115: 260-267.
18. National Institute for Clinical Excellence (NICE) (2009) Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline CG82. http://www.nice.org.uk/Guidance/ CG82 (accessed 08.04.09.).
19. Patel, MX, David, AS (2005) Why aren't depots prescribed more often, and what can be done about it ? Adv Psychiatr Treat 11: 203-213.
20. Patel, MX, deZoysa, N., Baker, D., David, AS (2005) Depot antipsychotic medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs 12: 237-244.
21. Patel, MX, deZoysa, N., Bernadt, M., David, AS (2008 a) Patients' perspectives on adherence to antipsychotic medication: depots versus tablets. J Clin Psychiatry 69: 1548-1556.
22. Patel, MX, deZoysa, N., Bernadt, M., David, AS (2008 b) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol [published online ahead of print 26 June 2008, doi: 10.1177/0269881108092124] (in press).
23. Patel, MX, Nikolaou, V., David, AS (2003 a) Psychiatrists attitudes to maintenance medication for patients with schizophrenia. Psychol Med 33: 83-89.
24. Patel, MX, Nikolaou, V., David, AS (2003 b) Eliciting psychiatrists' beliefs about side effects of typical and atypical antipsychotic drugs. Int J Psychiatry Clin Pract 7: 117-120.
25. Patel, MX, Young, C., Samele, C., Taylor, DM, David, AS (2004) Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol 19: 233-239.
26. Prescribing Observatory for Mental Health (POMH) (2008) High dose and combined antipsychotics in acute adult inpatient settings. http://www.rcpsych. ac.uk/PDF/Topic%201%20leaflet.pdf (accessed 01.06.08.).
27. Shi, L., Ascher-Svanum, H., Zhu, B., Faries, D., Montgomery, W., Marder, SR (2007) Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 58: 482-488.
28. Tattan, TMG, Creed, FH (2001) Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 27: 149-155.
29. Taylor, DM, Young, C., Patel, MX (2006) Risperidone long acting injection - prospective, six-month follow up of 250 patients. Int J Neuropsychopharmacol 9: 685-694.
30. Valenstein, M., Ganoczy, D., McCarthy, JF, Myra Kim, H., Lee, TA, Blow, FC (2006) Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 67: 1542-1550.
31. Vaughan, K., McConaghy, N., Wolf, C., Myhr, C., Black, T. (2000) Community treatment orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission. Aust N Z J Psychiatry 34: 801-808.
32. Walburn, J., Gray, R., Gournay, K., Quraishi, S., David, AS (2001) A systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179: 300-307.
33. Wistedt, B. (1995) How does the psychiatric patient feel about depot treatment, compulsion or help? Nord J Psychiatry 49 (Suppl. 35). 41-46.
34. Young, JL, Spitz, RT, Hillbrand, M., Daneri, G. (1999) Medication adherence failure in schizophrenia: a forensic review of rates, reasons, treatments and prospects. J Am Acad Psychiatry Law 27: 426-444.
35. Young, JL, Zonana, HV, Shepler, L. (1986) Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 14: 105-122.